盐酸哌甲酯缓释剂治疗注意缺陷多动障碍儿童疗效的国内临床研究

Efficacy of Methylphenidate Hydrochloride Sustained Release in the Treatment of Children with Attention Deficit Hyperactivity Disorder

摘要: 目的：检验优宁睿盐酸哌甲酯缓释咀嚼片和盐酸哌甲酯缓释干混悬剂在国内治疗注意缺陷多动障碍(ADHD)患儿核心症状和行为改善效果，为国内ADHD临床干预提供更多依据。方法：选取2025年2月~5月西南儿童康复医院发育行为门诊ADHD患儿为研究对象，根据患儿药物基因学组检测和血药浓度监测进行个性化滴定，使患儿体内的盐酸哌甲酯到达最佳治疗剂量。采用SNAP-IV评定量表和IVA-CPT测验进行症状和行为评估，12周治疗后对ADHD患儿进行复评。结果：12周治疗后SNAP-IV评定量表总分及各维度分显著降低(p < 0.001)，IVA-CPT测验控制力商数(p < 0.001)和注意力商数(p < 0.001)显著提高。结论：盐酸哌甲酯缓释咀嚼片和盐酸哌甲酯缓释干混悬剂在国内ADHD患儿中效果显著，能够有效改善注意缺陷和多动、冲动症状和行为。

Abstract: Objective: To test the effect of youningrui methylphenidate hydrochloride sustained-release chewable tablets and methylphenidate hydrochloride sustained-release dry suspension in the treatment of core symptoms and behavior improvement in children with attention deficit hyperactivity disorder (ADHD) in China, and to provide more basis for clinical intervention of ADHD in China. Methods: Children with ADHD in the developmental behavior clinic of Southwest Children’s Rehabilitation Hospital from February to May 2025 were selected as the research objects. Personalized titration was carried out according to the children’s drug genetic group detection and blood drug concentration monitoring, so that the children’s methylphenidate hydrochloride could reach the optimal therapeutic dose. The symptoms and behaviors of ADHD children were evaluated by the SNAP-IV rating scale and the IVA-CPT test. The children with ADHD were reevaluated after 12 weeks of treatment. Results: After 12 weeks of treatment, the total score and each dimension score of SNAP-IV were significantly decreased (p < 0.001), and the control quotient (p < 0.001) and attention quotient (p < 0.001) of the IVA-CPT test were significantly improved. Conclusion: Methylphenidate hydrochloride sustained-release chewable tablets and methylphenidate hydrochloride sustained-release dry suspension have significant effects in children with ADHD in China, and can effectively improve the symptoms and behaviors of attention deficit, hyperactivity and impulsivity.